All News
Long-Term Hydroxychloroquine Retinopathy Risk
MedPage Today
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
Read Article
Emergencies, Independence & Hemorrhage (1.23.2026)
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com
Read Article
APPs in the News (12.5.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salary concerns.
Read Article
Long-Term Hydroxychloroquine Retinopathy Risk
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
https://t.co/TBSTIb29Pf https://t.co/7TYQe4N4JH
Dr. John Cush RheumNow ( View Tweet)
Long-Term Hydroxychloroquine Retinopathy Risk
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
https://t.co/Gp6o0FfEYA https://t.co/TjLNXl229v
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of Dry Eye Autoimmune Disease
Rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung https://t.co/Z8ZBGmqT93
Dr. John Cush RheumNow ( View Tweet)
Nice simple overview of SCLERITIS. https://t.co/BOgZK8y4Qq https://t.co/P0dLtA3nKy
Links:
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of Dry Eye Autoimmune Disease
Rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung https://t.co/lnacSUlrI8
Dr. John Cush RheumNow ( View Tweet)
Nice simple overview of SCLERITIS. https://t.co/ndnfi6nZuA https://t.co/bzkOgupk7C
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Sjogren's Beyond the Dryness
Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness.
https://t.co/2U4Q2aRFec https://t.co/AGq36PT9iZ
Dr. John Cush RheumNow ( View Tweet)
JAMA -- Full read review "Uveitis in Adults:"
- affects adults 20 to 50 years
- noninfectious anterior uveitis: corticosteroids 1st line Rx
- posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line
https://t.co/BJQkPtK2z2 https://t.co/0puqX5iieE
Links:
Dr. John Cush RheumNow ( View Tweet)
PROSPERO metanalysis of 22 studies & 2208 JIA associated uveitis (JIAU) showed severe visual impairment in 16.6% at ~18 yrs. Most frequent: Cataract (44.3%), followed by glaucoma, synechiae, band keratopathy and hypotony. Biologics were protective https://t.co/6OoupX64NE https://t.co/7bp0JtRken
Dr. John Cush RheumNow ( View Tweet)
PROSPERO metanalysis of 22 studies & 2208 JIA associated uveitis (JIAU) showed severe visual impairment in 16.6% at ~18 yrs. Most frequent: Cataract (44.3%), followed by glaucoma, synechiae, band keratopathy and hypotony. Biologics were protective https://t.co/6OoupX64NE https://t.co/4GFnugdvod
Dr. John Cush RheumNow ( View Tweet)
ILD in Patients with Connective Tissue Disease
Dr. Janet Pope reports on abstract 0154 (Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States) at #ACR25.
https://t.co/WrJhsMizwV https://t.co/rkFny5ZjZQ
Dr. John Cush RheumNow ( View Tweet)
Organ Involvement with Behçet’s
A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages. https://t.co/jqM4IZuobe
Dr. John Cush RheumNow ( View Tweet)
Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy?
Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2
Very decent on primary (ESSDAI) & we will see this
Salivary flow only improved when some at baseline
#ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh
Links:
David Liew drdavidliew ( View Tweet)
Predictors of retinopathy progression after HCQ discontinued?
In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c
Age - significant assoc'n with progression
✳️monitor toxicity more closely esp in older pts
#ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
sheila RHEUMarampa ( View Tweet)
Is tocilizumab equally effective in ischemic vs. non-ischemic GCA?
Ischemic = vision, jaw claudication, or CVA
Remission at 6 mo higher in non-ischemic group then with equalization at month 12
No major difference in GCs at month 12
@RheumNow #ACR25 #Abst0739 https://t.co/OeYggSQYx8
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Nice SRMA evaluating HCQ dosing
>5mg/kg associated w/3.8x risk of retinopathy...
...but <5mg/kg associated w/1.8x risk of SLE flares
Morbidity from one of those is easily avoided by regular screening; morbidity from the other can be devastating
@RheumNow #ACR25 Abstr#805 https://t.co/1vJXxXqiRC
Mike Putman EBRheum ( View Tweet)
In case there was any doubt:
GCA leads to ischemic vision loss
PMR does not
#ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl
David Liew drdavidliew ( View Tweet)
